Novartis AG to buy out Cambridge cancer drug firm, CoStim Pharma
The Swiss drug giant Novartis AG, moving to establish itself as a top player in the hot field of cancer treatment known as immunotherapy, on Monday said it had snapped up two-year-old CoStim Pharmaceuticals Inc., a venture-backed Cambridge biotech using research from Boston academic labs.
Ex-Genzyme chief gives $10m to MGH cancer unit
Retired biotechnology executive Henri A. Termeer, who built Genzyme Corp. into the largest US company specializing in drugs to treat rare genetic disorders, is donating $10 million to Massachusetts General Hospital to establish it as a world leader in personalized medicine.
Larry Summers to Lead Obama’s Economic Council
With his appointment Monday to lead the National Economic Council, the brainy but abrasive Lawrence H. Summers ’75 is set to become a key ideas man for President-elect Barack Obama as he labors to keep the economic crisis from spiraling out of control.
Business Schools Counsel Grads in Financial Crisis
Last week, Harvard Business School mounted its own emergency rescue mission on Wall Street.
Sloan Students Hunt for Jobs In California ‘Valley Tech Trek’
The annual mating ritual between elite business schools and the talent-hungry technology industry this year lured a record 115 master of business administration candidates from MIT’s Sloan School of Management in Cambridge to the hillside campus of VMware Inc., one of Silicon Valley’s hottest companies.
Media Lab Making Light, Cheap, Foldable Electric Car
Will the car of the future be foldable?
CEOs, Faculty Join in Search For MIT Sloan Dean
MIT’s Sloan School of Management is opening a search for a new dean to succeed Richard L. Schmalensee ’65, who is scheduled to step down in June after nine years at the helm of the business school.
MIT Kerberos Consortium Plans Software Upgrade
Kerberos, a 20-year-old computer security technology with MIT roots, is about to be turbocharged for the mobile Internet era.
New Sloan Dean Selected From Wharton School Administration
MIT officials have tapped an outsider, David C. Schmittlein, deputy dean of the elite Wharton School at the University of Pennsylvania, to lead MIT’s Sloan School of Management.
Preferential Treatment May Impact Buyers
Envy is a powerful force in the human psyche — and a tool to be exploited in marketing.
Academics' Work Choices Raise Ethicists' Eyebrows
A high-powered academic team's work for a billionaire executive facing charges of improper accounting has raised questions about the appropriate relationship between academic consultants and the businesses they advise.